Biocept, Inc. announces availability of its new breast cancer test, OncoCEE-BR™ utilizing circulating tumor cells (CTCs) Capture, detection and enumeration Determination of HER2/neu status Biocept, Inc., an advanced diagnostic CLIA-certified service laboratory developing novel tests for the
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 status in Breast Cancer Patients San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
Biocept Announces Allowance of Key Patent for its Circulating Tumor Cell Platform San Diego, California: ? Biocept, Inc., a privately?held CLIA?certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in blood samples from cancer patients,
Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs) San Diego, CA ? Biocept, Inc. today reported that its scientists and academic collaborators will present three posters at the 34th annual San Antonio Breast Cancer
Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately?held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells in cancer patients, announced
Clarient, Inc., a GE company, announces the launch of Biocept’s proprietary Circulating Tumor Cells (CTC) test for HER2 status in breast cancer patient San Diego and Aliso Viejo, California: – Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and
Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its
Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on
Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting San Diego, California – Biocept, Inc., a CLIA-certified laboratory testing company focused on oncology diagnostics, specifically the detection and analysis
